In the afternoon, stocks related to the innovative drug concept staged a rebound, with Henglikang, a prominent player in the sector, reaching its daily trading limit and setting a new all-time high. Earlier, Hanshang Group had notched up two consecutive daily limits, while shares of Jincheng Pharmaceutical, Olymbio, and Jiankai Technology surged by over 10%. Borui Pharmaceutical, Kangchen Pharmaceutical, Qianhong Pharmaceutical, and Jibeier also joined the rally with notable gains. On the market news front, the 11th batch of national centralized drug procurement recently commenced, adhering to the principles of "stabilizing clinical use, ensuring quality, preventing collusion, and opposing internal competition." Prior to this, the National Healthcare Security Administration introduced a commercial insurance innovative drug catalog, marking the inception of China's dual-track payment system, which combines "basic medical insurance for essentials" with "commercial insurance catalog for high-value innovative drugs." This development heralds new growth opportunities for the innovative drug market.